S G Eckhardt
Overview
Explore the profile of S G Eckhardt including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
63
Citations
1599
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Von Hoff D, Clark G, Coltman C, Disis M, Eckhardt S, Ellis L, et al.
Clin Cancer Res
. 2021 Jul;
27(20):5472-5481.
PMID: 34312215
To address the need for clinical investigators in oncology, American Association for Cancer Research (AACR) and American Society for Clinical Oncology (ASCO) established the Methods in Clinical Cancer Research Workshop...
2.
Capasso A, LANG J, Pitts T, Jordan K, Lieu C, Davis S, et al.
J Immunother Cancer
. 2019 Feb;
7(1):37.
PMID: 30736857
Background: The success of agents that reverse T-cell inhibitory signals, such as anti-PD-1/PD-L1 therapies, has reinvigorated cancer immunotherapy research. However, since only a minority of patients respond to single-agent therapies,...
3.
Diamond J, Eckhardt S, Pitts T, Van Bokhoven A, Aisner D, Gustafson D, et al.
Breast Cancer Res
. 2018 Aug;
20(1):82.
PMID: 30071865
Background: Triple-negative breast cancer (TNBC) remains an aggressive breast cancer subtype with limited treatment options. ENMD-2076 is a small-molecule inhibitor of Aurora and angiogenic kinases with proapoptotic and antiproliferative activity...
4.
Arcaroli J, Quackenbush K, Purkey A, Powell R, Pitts T, Bagby S, et al.
Br J Cancer
. 2013 Jul;
109(3):667-75.
PMID: 23868008
Background: Dysregulation of the Notch pathway has been identified to play an important role in the development and progression of colorectal cancer (CRC). In this study, we used a patient-derived...
5.
Davis S, Eckhardt S, Messersmith W, Jimeno A
Drugs Today (Barc)
. 2013 Mar;
49(2):105-15.
PMID: 23462625
Regorafenib is a novel multikinase inhibitor that has demonstrated broad antitumor activity across various solid tumor types, in preclinical and clinical studies. Preclinical data show inhibitory activity of angiogenic, stromal...
6.
Leong S, Eckhardt S, Chan E, Messersmith W, Spratlin J, Camidge D, et al.
Cancer Chemother Pharmacol
. 2012 May;
70(1):65-74.
PMID: 22623210
Purpose: This phase I study assessed the safety, tolerability, maximum tolerated dose (MTD), pharmacokinetics, and preliminary antitumor effects of sunitinib combined with modified FOLFOX6 (mFOLFOX6). Methods: Patients with advanced solid...
7.
Harry B, Smith M, Burton Jr J, Dasari A, Eckhardt S, Diamond J
Curr Oncol
. 2012 Feb;
19(1):e36-41.
PMID: 22328846
Pseudocirrhosis is a rare form of liver disease that can cause clinical symptoms and radiographic signs of cirrhosis; however, its histologic features suggest a distinct pathologic process. In the setting...
8.
Pan Y, Xu R, Peach M, Huang C, Branstetter D, Novotny W, et al.
Br J Cancer
. 2011 Oct;
105(12):1830-8.
PMID: 22033270
Background: Dulanermin (rhApo2L/TRAIL) induces apoptosis by binding to death receptors DR4 and DR5, leading to caspase activation and subsequent cell death. A Phase1a trial evaluated the safety and tolerability of...
9.
Gore L, Rivera E, Basche M, Moulder-Thompson S, Li J, Eppers S, et al.
Invest New Drugs
. 2011 Sep;
30(5):1942-9.
PMID: 21931969
Background: To determine the maximum tolerated dose (MTD), safety and pharmacokinetics of trabectedin with capecitabine in patients with advanced malignancies. Design: In this Phase I, open-label, dose-finding study, patients refractory...
10.
Infante J, Kurzrock R, Spratlin J, Burris H, Eckhardt S, Li J, et al.
Cancer Chemother Pharmacol
. 2011 Jun;
69(1):165-72.
PMID: 21638123
Purpose: Inhibition of kinesin spindle protein or Eg5 causes the formation of monoastral mitotic spindles, which leads to cell death. AZD4877 is a specific, potent inhibitor of Eg5. Methods: This...